Johnson and Johnson, along with global partners, announced results from the phase 2b Imbokodo study (also known as HVTN 705/HPX2008, which evaluated the company’s investigational…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.